Case 1: Alzheimer’s disease
What is Alzheimer’s disease (AD)?
= An irreversible, progressive brain disorder that accounts for
60-70% of all cases of dementia (10-20% is vascular
dementia)
= 47 million people worldwide suffer from dementia (2015)
which costs 818 billion dollars → 85% of costs are related to
family and social, rather dan medical care
- Tripled by 2050
- Every 3 seconds new cases are diagnosed
- No treatment for AD
- Not all subjects with amyloid plaques suffer from
dementia
= NOT the same as dementia → all people with
Alzheimer suffer from dementia, but not all
dementia cases are due to Alzheimer pathology
= Key messages about its rising problem:
• People + 45 years without dementia need
active treatment against hypertension →
reduces dementia incidence
• People with AD or dementia (Lewy) need:
o Cholinesterase inhibitors at all
stages
▪ Not effective in mild
cognitive impairments
o Memantine for severe dementia
• Good dementia care: medical, supportive, and social care → should be tailored to
unique individual and cultural needs, preferences
• Family carers are at high risk of depression: effective interventions, including
STrAtegies for RelaTives (START) reduce the risk of depression,
,Hallmarks
Three hallmarks
1. Brain atrophy
- Shrinkage of the brain → 2 typical places: cerebral cortex + hippocampus
- Enlarged ventricles (fluid filled cavities)
2. Extracellular aggregates of amyloid β (Aβ) plaques
- Amyloid cascade hypothesis synthesizes histopathological and genetic information,
and posits that the deposition of the amyloid-β peptide in the brain parenchyma
initiates a sequence of events that ultimately lead to AD dementia
= Normally: APP gets cleaved by a-secretase
→ sAPP (soluble) and helps neurons grow and
repair
= Due to a mutation gene that codes APP +
PSEN 1/2 (Amyloid Precursor Protein), APP
gets cleaved by β+g-secretase → Aβ (amyloid
beta), non-soluble → very hydrophobic and
sticky oligomerization (aggregation) →
- Aβ plaque formation + deposition
outside of neuron → disrupt signaling
between neurons
- Triggers cascade of formation of
neurofibrillary tangles (NFT’s) inside
the neuron
1. AB40: normal
2. AB42: more pathogenic form → are longer
,→ aggregate stress → PHF (paired
helical filaments) formation (= TAU
proteins) → mediates neuronal
death or affects synaptic
neurotransmission → dementia
3. Intracellular neurofibrillary tangles made of hyperphosphorylated
tau-protein (Tau tangles)
- Tau: normally stabilizes the microtubule in axons
- But due to the formation of Aβ, kinase in the neuron
gets triggered hyper phosphorylates the tau protein
→ gets sticky and changes its shape and gets of the
microtubule → loses its function of stabilization →
gets tangled, clumped together (neurofibrillary
tangles)
Symptoms
- First symptoms: mild cognitive difficulties
• Up to 8 years before a person fulfills the clinical criteria for diagnosis of AD
• Short term memory loss, subtle problems with attentiveness, planning, abstract
thinking
• Effects the most complex activities of daily living (ADL)
- Early stage: increasing impairment of learning and memory
• Shrinking vocabulary, decreased word fluency
- Middle stage: progressive deterioration eventually hinders independence, with
subjects being unable to perform most common activities of daily living.
• Behavioral and neuropsychiatric changes become more prevalent: wandering,
irritability, emotional lability, leading to crying and aggression
• Long term memory becomes impaired, paraphasia (the incorrect word
substitutions), loss of reading and writing skills, failing to recognize close relatives
- Late stage/ final stage/ severe stage: complete dependence on caregivers
, • Language is reduced to simple phrases (even single words), complete loss of
speech, but can still understand and return emotional signals, aggressiveness,
extreme apathy (lack of feeling), exhaustion
Biomarkers
- Imaging biomarkers:
▪ Medial temporal lobe (memory) atrophy
▪ Hippocampal volume: decreasing
→ Via MRI
→ Via PET-scan: PiB (levels of AB) or FDG PET (measures glucose
consumption, the energy metabolism)
- Fluid biomarkers: sample of CSF via lumbar puncture
▪ Decrease of Amyloid B 42 (AB42)
▪ Increase of tTau and pTau (phosphorylated tau)
→ No blood tests
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller HealthScienceStudent. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $7.29. You're not tied to anything after your purchase.